Finch Therapeutics Group Inc Share Price Today: Live Updates & Key Insights

Finch Therapeutics Group Inc share price today is $1.82, up -9.09%. The stock opened at $1.73 against the previous close of $1.98, with an intraday high of $2.22 and low of $1.39.

Finch Therapeutics Group Inc Share Price Chart

Finch Therapeutics Group Inc

us-stock
To Invest in {{usstockname}}
us-stock

Finch Therapeutics Group Inc Share Price Performance

$1.82 -0.0909(-9.09%) FNCH at 23 Mar 2026 01:08 PM Biotechnology
Lowest Today 1.39
Highest Today 2.22
Today’s Open 1.73
Prev. Close 1.98
52 Week High 16.74
52 Week Low 1.39
Day’s Range: Low 1.39 High 2.22
52-Week Range: Low 1.39 High 16.74
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

Finch Therapeutics Group Inc Institutional Holdings

Susquehanna International Group, LLP 3.68

Vanguard Group Inc 2.26

Vanguard Institutional Extnd Mkt Idx Tr 1.01

Renaissance Technologies Corp 0.73

Vanguard Total Stock Mkt Idx Inv 0.60

Greenwich Ivy Long-Short Instl 0.47

Ikarian Capital, LLC 0.43

Fidelity Extended Market Index 0.23

Tower Research Capital LLC 0.16

Fidelity Total Market Index 0.10

Bleichroeder LP 0.06

Fidelity Nasdaq Composite Index 0.05

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

Spartan Total Market Index Pool E 0.03

BlackRock Inc 0.02

NT Ext Equity Mkt Idx Fd - NL 0.01

Fidelity Series Total Market Index 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

Northwestern Mutual Wealth Management Co 0.01

Morgan Stanley - Brokerage Accounts 0.01

SSgA U.S. Extended Market Index Class I 0.01

State St US Extended Mkt Indx NL Cl C 0.01

SSgA U.S. Total Market Index Strategy 0.00

State St US Ttl Mkt Indx SL Cl I 0.00

Northern Trust Wilshire 5000 0.00

NT US Market Cap Idx Fd - L 0.00

Royal Bank of Canada 0.00

BlackRock Extended Mkt Composite 0.00

Bank of America Corp 0.00

BNYM Mellon NSL Mkt Completion Fund Inst 0.00

Wells Fargo & Co 0.00

Cutler Group LP 0.00

Moisand Fitzgerald Tamayo, LLC 0.00

UBS Group AG 0.00

Ancora Advisors LLC 0.00

Baupost Group LLC 0.00

LAKE STREET ADVISORS GROUP, LLC 0.00

MSD Partners, L.P. 0.00

Steward Partners Investment Advisory, LLC 0.00

Finch Therapeutics Group Inc Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Finch Therapeutics Group Inc Fundamentals

Market Cap 3.18 M

PB Ratio 0.1424

PE Ratio 0.0

Enterprise Value 11.98 M

Total Assets 71.00 M

Volume 629479

Finch Therapeutics Group Inc Company Financials

Annual Revenue FY23:115000 0.1M, FY22:861000 0.9M, FY21:18532000 18.5M, FY20:7719000 7.7M, FY19:10154000 10.2M

Annual Profit FY23:null 0.0M, FY22:861000 0.9M, FY21:18532000 18.5M, FY20:7719000 7.7M, FY19:9840000 9.8M

Annual Net worth FY23:-98721000 -98.7M, FY22:-113699000 -113.7M, FY21:-55859000 -55.9M, FY20:-39248000 -39.2M, FY19:-20406000 -20.4M

Quarterly Revenue Q1/2024:0 0.0M, Q4/2023:2845000 2.8M, Q3/2023:0 0.0M, Q2/2023:0 0.0M, Q1/2023:107000 0.1M

Quarterly Profit Q1/2024:-43000 -0.0M, Q4/2023:2801000 2.8M, Q3/2023:null 0.0M, Q2/2023:null 0.0M, Q1/2023:107000 0.1M

Quarterly Net worth Q1/2024:-3876000 -3.9M, Q4/2023:-3041000 -3.0M, Q3/2023:-2416000 -2.4M, Q2/2023:-6950000 -7.0M, Q1/2023:-63939000 -63.9M

About Finch Therapeutics Group Inc & investment objective

Company Information Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Organisation Biotechnology

Employees 1

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Finch Therapeutics Group Inc FAQs

What is the share price of Finch Therapeutics Group Inc today?

The current share price of Finch Therapeutics Group Inc is $1.82.

Can I buy Finch Therapeutics Group Inc shares in India?

Yes, Indian investors can buy Finch Therapeutics Group Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Finch Therapeutics Group Inc shares in India?

You can easily invest in Finch Therapeutics Group Inc shares from India by:

Can I buy fractional shares of Finch Therapeutics Group Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Finch Therapeutics Group Inc?

Finch Therapeutics Group Inc has a market cap of $3.18 M.

In which sector does Finch Therapeutics Group Inc belong?

Finch Therapeutics Group Inc operates in the Biotechnology sector.

What documents are required to invest in Finch Therapeutics Group Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Finch Therapeutics Group Inc?

The PE ratio of Finch Therapeutics Group Inc is N/A and the PB ratio is 0.14.